Abilify MyCite (Aripiprazole): A Critical Evaluation of the Novel Dosage Form.
Shukla AK, Mehani R, Sadasivam B.
J Clin Psychopharmacol · letter · DOI 10.1097/jcp.0000000000001334 PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för aripiprazole. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
31 hitsA safety evaluation of aripiprazole in the treatment of schizophrenia.
Preda A, Shapiro BB.
Expert Opin Drug Saf · review; journal article · DOI 10.1080/14740338.2020.1832990A 3-year prospective study on the metabolic effect of aripiprazole, quetiapine and ziprasidone: A pragmatic clinical trial in first episode psychosis patients.
Vázquez-Bourgon J, Ibáñez Alario M, Mayoral-van Son J, Gómez Revuelta M, Ayesa Arriola R, Juncal Ruiz M, Ortiz-García de la Foz V, Crespo Facorro B.
Eur Neuropsychopharmacol · research support, non-u.s. gov't; pragmatic clinical trial; journal article · DOI 10.1016/j.euroneuro.2020.08.009Long-Acting Injectable (LAI) Aripiprazole Formulations in the Treatment of Schizophrenia and Bipolar Disorder: a Systematic Review.
Rapinesi C, Kotzalidis GD, Mazzarini L, Brugnoli R, Ferracuti S, De Filippis S, Cuomo I, Giordano G, Del Casale A, Angeletti G, Sani G, Girardi P.
Clin Drug Investig · systematic review; journal article · DOI 10.1007/s40261-019-00801-9Digital aripiprazole or digital evergreening? A systematic review of the evidence and its dissemination in the scientific literature and in the media.
Cosgrove L, Cristea IA, Shaughnessy AF, Mintzes B, Naudet F.
BMJ Evid Based Med · systematic review; journal article · DOI 10.1136/bmjebm-2019-111204Aripiprazole with digital ingestion tracking (Abilify MyCite).
Författaruppgift saknas
Med Lett Drugs Ther · review; journal articleAnalysis of the Binding of Aripiprazole to Human Serum Albumin: The Importance of a Chloro-Group in the Chemical Structure.
Sakurama K, Kawai A, Tuan Giam Chuang V, Kanamori Y, Osa M, Taguchi K, Seo H, Maruyama T, Imoto S, Yamasaki K, Otagiri M.
ACS Omega · research-article; journal article · DOI 10.1021/acsomega.8b02057Process control and in vitro/in vivo evaluation of aripiprazole sustained-release microcrystals for intramuscular injection.
Cai Q, He L, Wang S, Chu W, Zhou L, Pan W, Zhang L, Jiang S, Ma D, Liang X, Gou J, Yin T, Zhang Y, Tang X, He H.
Eur J Pharm Sci · journal article · DOI 10.1016/j.ejps.2018.09.017Aripiprazole: a drug with a novel mechanism of action and possible efficacy for alcohol dependence.
Vergne DE, Anton RF.
CNS Neurol Disord Drug Targets · review; journal article; research support, n.i.h., extramural · DOI 10.2174/187152710790966731Treating bipolar disorder in the primary care setting: the role of aripiprazole.
Manning JS, McElroy SL.
Prim Care Companion J Clin Psychiatry · research-article; journal article · DOI 10.4088/pcc.08r00635Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia.
Yang TT, Wang SJ.
Synapse · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1002/syn.20548A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, Marcus R, McQuade RD, Iwamoto T, Carson WH.
Am J Psychiatry · comparative study; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article; research support, n.i.h., extramural · DOI 10.1176/appi.ajp.2008.07061035Aripiprazole versus typical antipsychotic drugs for schizophrenia.
Bhattacharjee J, El-Sayeh HG.
Cochrane Database Syst Rev · systematic review; systematic-review; journal article · DOI 10.1002/14651858.cd006617.pub3Aripiprazole: in major depressive disorder.
Weber J, Lyseng-Williamson KA, Scott LJ.
CNS Drugs · review; journal article · DOI 10.2165/00023210-200822100-00002Aripiprazole, an atypical antipsychotic, prevents the motor hyperactivity induced by psychotomimetics and psychostimulants in mice.
Leite JV, Guimarães FS, Moreira FA.
Eur J Pharmacol · research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2007.09.016Aripiprazole acts as a selective dopamine D2 receptor partial agonist.
Wood M, Reavill C.
Expert Opin Investig Drugs · review; journal article · DOI 10.1517/13543784.16.6.771Aripiprazole: pharmacology and evidence in bipolar disorder.
McIntyre RS, Soczynska JK, Woldeyohannes HO, Miranda A, Konarski JZ.
Expert Opin Pharmacother · research support, non-u.s. gov't; review; journal article · DOI 10.1517/14656566.8.7.1001Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine.
Stoops WW.
Exp Clin Psychopharmacol · journal article; research support, n.i.h., extramural · DOI 10.1037/1064-1297.14.4.413Aripiprazole for schizophrenia. Systematic review.
El-Sayeh HG, Morganti C, Adams CE.
Br J Psychiatry · research support, non-u.s. gov't; systematic review; journal article · DOI 10.1192/bjp.189.2.102Aripiprazole in the acute treatment of male patients with schizophrenia: effectiveness, acceptability, and risks in the inner-city hospital setting.
Dratcu L, Olowu P, Hawramy M, Konstantinidou C.
Neuropsychiatr Dis Treat · research-article; journal article · DOI 10.2147/nedt.2006.2.2.191Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study.
Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P.
Am J Psychiatry · randomized controlled trial; journal article · DOI 10.1176/ajp.2006.163.5.833Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways.
Urban JD, Vargas GA, von Zastrow M, Mailman RB.
Neuropsychopharmacology · journal article; research support, n.i.h., extramural · DOI 10.1038/sj.npp.1301071Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia.
Gründer G, Kungel M, Ebrecht M, Göröcs T, Modell S.
Pharmacopsychiatry · journal article · DOI 10.1055/s-2006-931485Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study.
Sachs G, Sanchez R, Marcus R, Stock E, McQuade R, Carson W, Abou-Gharbia N, Impellizzeri C, Kaplita S, Rollin L, Iwamoto T, Aripiprazole Study Group.
J Psychopharmacol · multicenter study; randomized controlled trial; journal article · DOI 10.1177/0269881106059693[A new atypical antipsychotic with partial dopamine agonist effect (aripiprazole)].
Kerpel-Fronius S, Lóránt M.
Neuropsychopharmacol Hung · review; journal articleAripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
Li Z, Ichikawa J, Dai J, Meltzer HY.
Eur J Pharmacol · comparative study; research support, non-u.s. gov't; journal article · DOI 10.1016/j.ejphar.2004.04.028The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T.
Brain Res · journal article · DOI 10.1016/j.brainres.2003.09.082Aripiprazole, a novel atypical antipsychotic drug.
Argo TR, Carnahan RM, Perry PJ.
Pharmacotherapy · clinical trial, phase iii; clinical trial, phase ii; clinical trial; multicenter study; randomized controlled trial; journal article · DOI 10.1592/phco.24.2.212.33145Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T, Perry CM.
Drugs · review; journal article · DOI 10.2165/00003495-200464150-00010Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology.
Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R.
Neuropsychopharmacology · research support, u.s. gov't, p.h.s.; research support, non-u.s. gov't; journal article · DOI 10.1038/sj.npp.1300203